iRhythm Holdings, Inc. research snapshot
IRTC AI stock analysis reads iRhythm Holdings, Inc. as the dominant player in patch-based long-term ambulatory cardiac monitoring, built around the Zio ECG platform and FDA-cleared AI analytics. At the August 4, 2026 data cutoff, IRTC traded near $122.43 with a market capitalization of about $4.02 billion. The positive case rests on 2025 revenue growth of 26.2% to $747.14 million, 2026 consensus revenue near $881 million, gross margin near 71%, a shrinking GAAP loss, positive free cash flow, and a Strong Buy analyst consensus with an average target of $177.07. The caution case is that IRTC is still GAAP unprofitable on a TTM basis, carries net debt of about $180 million, and faces a DOJ civil investigative demand, a securities class action settlement, a new shareholder fiduciary inquiry from July 2026, a June 2026 cybersecurity incident, an auditor change, and competition from Boston Scientific and Medtronic. The next binary catalyst is the Q2 2026 earnings report on August 6, 2026. This page is informational research, not investment advice.
Current price
$122.43 intraday reference
Market cap
$4.02 billion
AI score
61 / 100
Rating
High-growth ambulatory cardiac monitoring leader approaching breakeven, with expanding margins but legal, regulatory, and competitive overhangs
Trend status
Short-term bounce above the 50-day moving average, still well below the 200-day moving average and 52-week high
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | iRhythm sells an integrated ambulatory cardiac monitoring service: Zio ECG patches, AI analytics, and clinical reports. Revenue grew 26.2% in 2025 to $747.14 million and Q1 2026 revenue rose 25.7% year over year to $199.39 million, with gross margin near 71%. | High |
| Moat | The moat comes from FDA-cleared AI algorithms, a large real-world heartbeat database, cardiologist brand recognition, EHR workflow integration, and an estimated 72% share in the long-term continuous monitoring segment. Deep-pocketed competitors such as Boston Scientific and Medtronic are investing in competing patch solutions. | Medium |
| Management | Management is executing well on operations: a beat-and-raise Q1 2026, margin expansion, positive free cash flow, and the Zio MCT development program on track for a first-half 2027 launch. Governance is the weak point, with the class action settlement, DOJ civil investigative demand, June 2026 cyber incident, auditor change, and a July 2026 shareholder fiduciary inquiry. | Medium |
| Financial trend | TTM revenue is $787.85 million with a TTM GAAP net loss of $27.78 million. The full-year 2025 net loss improved to $44.55 million from $113.29 million in 2024, and 2026 consensus points near breakeven at a $1.91 million GAAP net loss on $881 million of revenue. Free cash flow was positive at $18.75 million TTM. | High |
| Valuation | At $122.43, IRTC trades at about 4.9x TTM sales, 4.2x forward sales, 23.9x book value, and a forward P/E near 364, with a negative TTM P/E. Enterprise value of about $4.0 to $4.2 billion is roughly 5.1x forward revenue. The market is paying up for a profitability inflection, not current earnings. | High |
| Technical trend | The stock bounced about 9% over five trading days to near $122, reclaiming the 50-day moving average of $114.01, with RSI(14) near 59 and stochastic readings in overbought territory. It remains about 13% below the 200-day moving average of $141.41 and about 42% below the 52-week high of $212. | Medium-high |
| Risk level | Main risks are the delayed GAAP profitability inflection, the DOJ civil investigative demand, the securities class action settlement and the new July 2026 fiduciary inquiry, the June 2026 cybersecurity incident, the auditor change, net debt of about $180 million, reimbursement dependence, and competitive pressure from Boston Scientific and Medtronic. | Medium-high |
| AI confidence | Descriptive confidence is high for reported financials, the quote, and technical levels. Return confidence is lower because the stock price depends on when iRhythm reaches sustained GAAP profitability and how legal, regulatory, reimbursement, and competitive events resolve. | High data confidence |
| Investment certainty | IRTC may appeal to growth investors who believe in the long-term cardiac monitoring thesis and the approaching profitability inflection, but it does not yet offer the certainty profile that suits value or income investors, given the legal overhang, net debt, and still-negative GAAP earnings. | Low to medium |
IRTC AI stock forecast
The IRTC AI stock forecast uses scenarios rather than a single price claim. Because IRTC still has negative TTM GAAP EPS, the framework uses revenue multiples, consensus estimates, and analyst targets as anchors. At the August 3, 2026 reference price of $122.43, 15 analysts average a $177.07 target, about 44.6% higher, with a range of $150 to $255. The scenarios below depend on the Q2 2026 report on August 6, the timeline to sustained GAAP profitability, the Zio MCT launch in the first half of 2027, reimbursement policy, and competitive intensity.
$175 to $215
More likely if Q2 2026 results on August 6 beat and management raises guidance again, GAAP profitability arrives by late 2026 or early 2027, margins keep expanding, the Zio MCT launch stays on track for the first half of 2027, the 200-day moving average near $141 is reclaimed, and the stock re-rates toward the higher analyst targets.
$150 to $185
More likely if iRhythm delivers near the 2026 consensus revenue of about $881 million with steady margin gains, GAAP losses continue narrowing toward breakeven, legal and regulatory items stay contained, and the average analyst target of about $177 proves achievable.
$95 to $120
More likely if the GAAP profitability inflection slips beyond 2027, the DOJ civil investigative demand or new fiduciary inquiry escalates, reimbursement tightens, Boston Scientific or Medtronic take meaningful share, or the stock breaks below the $100.85 52-week low.
IRTC AI technical analysis
IRTC AI technical analysis shows a short-term bounce inside a longer-term downtrend as of the August 4, 2026 data cutoff. StockAnalysis and Barchart showed an August 3, 2026 intraday reference near $122.43, up about 4.5% on the day, with a day range of $118.09 to $123.34. The stock has reclaimed the 50-day moving average of $114.01 after rising about 9% over five trading days, but it is still about 13% below the 200-day moving average of $141.41 and far below the 52-week high of $212.00. RSI(14) is near 59, short-term stochastic readings are overbought near 94%, and average daily range is about 4%. The Q2 2026 earnings report on August 6, 2026 is the next major volatility catalyst.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $122.43 intraday | StockAnalysis, Google Finance, and Yahoo Finance listed this reference on August 3, 2026, with a day range of $118.09 to $123.34 and a 4.5% gain for the day. |
| First support | $114.01 (50-day moving average) | The 50-day moving average sits near $114.01. The stock reclaimed this level on the recent bounce. A hold above it is a positive short-term sign. |
| Key support zone | $108.00 to $113.00 | This zone spans the June and early July consolidation area, including the June 24, 2026 close of $112.47. A pullback into this zone with strong earnings would be constructive. |
| Critical support | $100.85 (52-week low) | The 52-week low of $100.85 was set in 2026. This is the critical floor. A break below it would open much deeper downside. |
| Near resistance | $123.34 to $128.00 | The August 3 intraday high of $123.34 is the first near-term hurdle, followed by the year-to-date average price near $128. |
| Major resistance | $141.41 (200-day moving average) | The 200-day moving average near $141.41 is the key trend-defining level. The stock is about 13% below it, and a close above it would signal a potential trend change. |
| Upper resistance | $147.00 to $160.00 | Analyst price targets in this zone include Goldman Sachs at $147, Truist and Stephens at $160. A move here would require meaningful positive catalysts. |
| Moving averages | Above 50-day, below 200-day | Price is above the 50-day moving average of $114.01 but below the 100-day moving average of $116.55 and the 200-day moving average of $141.41. The structure is still a longer-term downtrend. |
| Momentum | RSI(14) near 59, stochastic near 94 | RSI(14) of about 59 is mildly bullish but short-term stochastic readings near 94% are overbought, raising the chance of a near-term pause or pullback. |
| Volume | Average volume near 500,000 to 580,000 shares | The 20-day average volume is about 502,000 to 501,681 shares, with the recent bounce supported by average to above-average volume. Short interest is about 10.4% of shares outstanding. |
| Volatility | High, with Q2 earnings on August 6, 2026 | Average true range is about $5.30 (roughly 4.3%) and historic volatility is about 44% to 48% annualized. The Q2 2026 report after the close on August 6 is the next major event. |
| Invalidation | Close below $100.85 or above $141.41 | A close below the 52-week low of $100.85 would invalidate the current support structure. A close above the 200-day moving average near $141.41 would suggest the downtrend may be reversing. |
IRTC AI trading strategy
The IRTC AI trading strategy below is a rules-based research framework, not personal advice. It connects price levels with the Q2 2026 earnings report on August 6, revenue growth, the GAAP profitability inflection, margin trajectory, the Zio MCT timeline, legal and regulatory events, and competitive dynamics.
Given that the stock is in a longer-term downtrend despite the recent bounce, a trend-following approach would wait for IRTC to hold above the 50-day moving average near $114, build a higher low, and ideally close above the 200-day moving average near $141 before treating the trend as up.
A break back below $114 and then below $100.85 should be respected as downside continuation. Position size should reflect the high single-stock volatility, the roughly 4.3% average daily range, and the pending earnings event.
If IRTC pulls back toward the $108 to $114 support zone and Q2 2026 results on August 6 confirm margin progress and guidance, a mean-reversion move back toward the $135 to $147 area could develop. Wait for confirmation signals rather than buying the dip on faith.
Do not assume support holds just because the stock already fell from $212 to $101. The remaining overhangs, including the DOJ civil investigative demand, the new fiduciary inquiry, net debt, and competition, are unresolved, so mean-reversion risk is elevated.
Track the Q2 2026 earnings report on August 6, 2026, 2026 revenue guidance and GAAP profitability timeline, Zio MCT development milestones toward a first-half 2027 launch, reimbursement and LCD updates, the DOJ civil investigative demand, the securities class action settlement and the July 2026 fiduciary inquiry, cybersecurity disclosures, and competitive moves from Boston Scientific and Medtronic.
The stock carries binary event risk around earnings, FDA and reimbursement news, and legal developments. Consider smaller positions ahead of the August 6 earnings report and avoid leveraged exposure.
Investment research summary
iRhythm gets paid because cardiologists and health systems need reliable, continuous, AI-enhanced ambulatory cardiac monitoring to detect arrhythmias. Patients wear a Zio patch for up to 14 days, and iRhythm provides the device, the AI analysis of millions of heartbeats, and the clinical report as one integrated service, holding roughly 72% of the long-term continuous monitoring segment.
The moat comes from FDA-cleared AI algorithms trained on a large real-world heartbeat database, brand recognition among cardiologists, ZioSuite integration with EHR workflows, and physician stickiness. The risk is that larger competitors with more capital, such as Boston Scientific and Medtronic, are investing in competing patch-based solutions.
The thesis fails if GAAP profitability keeps getting delayed beyond 2027, the DOJ civil investigative demand or the July 2026 fiduciary inquiry escalates into material costs or restrictions, reimbursement tightens and pushes customers to lower-margin models, a major competitor takes meaningful share, or the net debt position forces dilutive financing.
Management has delivered a beat-and-raise Q1 2026, margin expansion, and positive free cash flow, and it is steering the Zio MCT program toward a first-half 2027 launch. The weak point is governance: the securities class action settlement, the DOJ civil investigative demand, the June 2026 cybersecurity incident, the auditor change, and the new July 2026 shareholder fiduciary inquiry.
The shift from short-duration Holter and event monitors to longer-term patch-based continuous cardiac monitoring is a structural trend supported by an aging population, rising atrial fibrillation prevalence, and telemedicine adoption. The global ECG patch and Holter monitor market is projected to reach about $3.92 billion by 2035 at a 9.2% CAGR, but large medtech incumbents are also targeting this opportunity.
At roughly 4.9x TTM sales, 4.2x forward sales, and a forward P/E near 364, IRTC is priced as a growth stock betting on a profitability inflection. Margin of safety is limited unless GAAP profitability arrives faster than expected. The valuation depends on the execution of the inflection, which carries legal, reimbursement, and competitive risk.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IRTC quote reference | $122.43 intraday on August 3, 2026 | StockAnalysis.com IRTC overview | August 4, 2026 |
| Market capitalization verification | $4.02B reported, calculated as $122.43 x 32.86M shares = $4.02B | Pineify verification, StockAnalysis.com, and Yahoo Finance | August 4, 2026 |
| Shares outstanding | 32.86 million shares, up 2.87% year over year | StockAnalysis.com IRTC statistics | August 4, 2026 |
| TTM revenue | $787.85 million | StockAnalysis.com and Yahoo Finance | August 4, 2026 |
| TTM GAAP net income and EPS | -$27.78 million net income and -$0.86 diluted EPS | StockAnalysis.com and Yahoo Finance | August 4, 2026 |
| Q1 2026 (quarter ended March 2026) | $199.39 million revenue and -$13.93 million GAAP net loss, revenue up 25.7% year over year | Google Finance IRTC financials and Q1 2026 earnings materials | August 4, 2026 |
| FY2025 revenue and net loss | $747.14 million revenue (up 26.2%) and -$44.55 million net loss, improved from -$113.29 million in 2024 | StockAnalysis.com IRTC forecast | August 4, 2026 |
| FY2026 consensus estimates | Revenue near $881 million (up about 17.9%) and GAAP net loss near -$1.91 million | StockAnalysis.com IRTC forecast, S&P Global data | August 4, 2026 |
| Cash, debt, and net cash | $549.62 million cash, $729.29 million total debt, and about -$179.67 million net cash | StockAnalysis.com IRTC statistics | August 4, 2026 |
| Analyst consensus | 15 analysts, Strong Buy consensus, average price target $177.07, range $150 to $255 | StockAnalysis.com IRTC forecast and Google Finance | August 4, 2026 |
| 52-week range | $100.85 to $212.00 | StockAnalysis.com, Yahoo Finance, and Google Finance | August 4, 2026 |
| Technical indicators | 50-day moving average $114.01, 200-day moving average $141.41, RSI(14) near 59 | StockAnalysis.com IRTC statistics and Barchart | August 4, 2026 |
| Next earnings date | Q2 2026 results on August 6, 2026 after market close | iRhythm Holdings press release via GlobeNewswire | August 4, 2026 |
This IRTC AI stock analysis is an informational research tool only. It is not investment advice, not a recommendation to buy or sell iRhythm Holdings, Inc., and not a promise of future returns. Forecasts are scenario-based estimates from available public data as of August 4, 2026 and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
